北京商报讯（记者 王蔓蕾）1月25日晚间，华大智造（688114）发布2025年年度业绩预告显示，经公司 初步测算，预计2025年年度实现归属净利润-2.73亿元至-2.21亿元，同比亏损减少54.56%—63.22%。 对于业绩变化的主要原因，华大智造表示，报告期内，公司制定了一系列"提质增效重回报"措施，包括 人效提升、研发聚焦、营销费用全周期管理等措施，导致公司相关的成本费用相比同期减少；由于美 元、欧元汇率波动，导致公司持有外币货币性项目产生的汇兑收益同比增加；上半年对以前年度涉及的 不确定性的税务争议风险相应的税务拨备进行冲回处理，导致所得税费用同比减少；根据企业会计准则 及公司会计政策等相关规定，基于谨慎性原则，公司对截至2025年12月31日合并报表范围内的各类资产 计提了减值准备的会计处理。 ...

华大智造(688114.SH)发布2025 年年度业绩预告，经初步测算，公司预计2025年年度实现归属于母公司 所有者的净利润为亏损2.21亿元到2.73亿元，与上年同期相比，亏损将减少3.28亿元到亏损减少3.80亿 元。报告期内，由于美元、欧元汇率波动，导致公司持有外币货币性项目产生的汇兑收益同比增加。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

证券代码：688114 证券简称：华大智造 公告编号：2026-001 深圳华大智造科技股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重点内容提示 ●公司经初步测算，深圳华大智造科技股份有限公司（以下简称"公司"）预 计2025年年度实现归属于母公司所有者的净利润与上年同期（法定披露数据）相比， 实现归属于母公司所有者的净利润-27,300.00万元到-22,100.00万元，与上年同期相 比，亏损将减少32,782.70万元到亏损减少37,982.70万元，同比亏损减少54.56%到亏 损减少63.22%。 ●公司预计 2025 年年度实现归属于母公司所有者的扣除非经常性损益的净利润 -39,700.00 万元到-32,200.00 万元，与上年同期相比，亏损将减少 25,570.68 万元到 亏损减少 33,070.68 万元，同比亏损减少 39.18%到亏损减少 50.67%。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告 ...

报告期内，公司制定了一系列"提质增效重回报"措施，包括人效提升、研发聚焦、营销费用全周期管理 等措施，导致公司相关的成本费用相比同期减少。报告期内，由于美元、欧元汇率波动，导致公司持有 外币货币性项目产生的汇兑收益同比增加。报告期内，上半年对以前年度涉及的不确定性的税务争议风 险相应的税务拨备进行冲回处理，导致所得税费用同比减少。根据企业会计准则及公司会计政策等相关 规定，基于谨慎性原则，公司对截至2025年12月31日合并报表范围内的各类资产计提了减值准备的会计 处理。 智通财经APP讯，华大智造(688114.SH)发布2025年年度业绩预告，经公司初步测算，预计2025年年度实 现归属于母公司所有者的净利润与上年同期(法定披露数据)相比，实现归属于母公司所有者的净利 润-27,300万元到-22,100万元，与上年同期相比，亏损将减少32,782.70万元到亏损减少37,982.70万元， 同比亏损减少54.56%到亏损减少63.22%。 ...

智通财经APP讯，华大智造(688114.SH)发布2025年年度业绩预告，经公司初步测算，预计2025年年度实 现归属于母公司所有者的净利润与上年同期(法定披露数据)相比，实现归属于母公司所有者的净利 润-27,300万元到-22,100万元，与上年同期相比，亏损将减少32,782.70万元到亏损减少37,982.70万元， 同比亏损减少54.56%到亏损减少63.22%。 报告期内，公司制定了一系列"提质增效重回报"措施，包括人效提升、研发聚焦、营销费用全周期管理 等措施，导致公司相关的成本费用相比同期减少。报告期内，由于美元、欧元汇率波动，导致公司持有 外币货币性项目产生的汇兑收益同比增加。报告期内，上半年对以前年度涉及的不确定性的税务争议风 险相应的税务拨备进行冲回处理，导致所得税费用同比减少。根据企业会计准则及公司会计政策等相关 规定，基于谨慎性原则，公司对截至2025年12月31日合并报表范围内的各类资产计提了减值准备的会计 处理。 ...

华大智造公告，预计2025年年度实现归属于母公司所有者的净利润与上年同期（法定披露数据）相比， 实现归属于母公司所有者的净利润-2.73亿元到-2.21亿元，与上年同期相比，亏损将减少3.28亿元到亏损 减少3.8亿元，同比亏损减少54.56%到亏损减少63.22%。 ...

Core Viewpoint - The article discusses the volatility and potential of AI application stocks, highlighting the recent surge and subsequent decline in their prices, emphasizing the need for logical investment rather than speculative trading [4][5][7]. Group 1: AI Application Market Dynamics - The AI application market experienced a significant surge starting January 9, driven by the IPO of MiniMax, which saw a price increase of over 90%, boosting market confidence in AI commercialization [5]. - Following the initial excitement, many AI application companies issued announcements clarifying their limited revenue from AI, leading to a sharp price correction in the sector [7]. - The article suggests that while the AI application sector is currently volatile, it has the potential to create long-term value if investors can identify companies with genuine business models and revenue streams [9]. Group 2: GEO Model in Advertising - The article introduces the GEO (Generative Engine Optimization) model, which allows users to input specific demands and receive optimized product recommendations directly from AI, streamlining the purchasing process [11]. - The GEO market is projected to grow significantly, with estimates of $2.9 billion in China and $11.2 billion globally by 2025, and reaching $24 billion and $100.7 billion by 2030 respectively [13]. - GEO is seen as a transformative force in marketing, shifting the power dynamics towards platforms that can leverage AI models effectively, similar to how Google and Baidu dominated the SEO era [16][17]. Group 3: AI in Healthcare - The AI healthcare sector has shown strong performance, with companies like Hongbo Medicine and Dian Diagnostics seeing stock increases of over 50% year-to-date [28]. - Government policies are increasingly supportive of AI in healthcare, with initiatives aimed at integrating AI into high-end medical equipment and remote healthcare applications [30]. - The article notes that AI healthcare applications are moving from concept to clinical use, with companies like Tempus AI reporting an 83% revenue growth, indicating a positive trend for domestic firms in the sector [31]. Group 4: AI in Financial Technology - The financial technology sector has also seen a rise, with the Financial Technology ETF increasing by over 14% since the beginning of 2026 [46]. - AI is expected to enhance the capabilities of internet financial companies by improving customer engagement and operational efficiency through advanced tools [48]. - However, the article cautions that while AI can improve operational efficiency, it may not fundamentally change the poor business models of many financial IT companies, which face challenges such as high customization costs and fragmented market share [49].

Core Viewpoint - The article discusses the volatility and potential of AI application stocks, highlighting the recent surge and subsequent decline in their prices, emphasizing the need for logical investment rather than speculative trading [3][4][6]. Group 1: AI Application Market Dynamics - The AI application market saw a significant surge starting January 9, driven by the IPO of MiniMax, which rose over 90%, boosting market confidence in AI commercialization [3][4]. - Following the initial excitement, many AI companies issued announcements clarifying their limited revenue from AI, leading to a sharp price correction in the sector [4][5]. - The article suggests that while the current market may present opportunities, investors should focus on companies with genuine value and sustainable business models [4][7]. Group 2: GEO Model in Advertising - The article introduces the GEO (Generative Engine Optimization) model as a transformative approach in advertising, allowing users to input specific demands and receive optimized product recommendations directly from AI [9][11]. - The GEO market is projected to grow significantly, with estimates of $2.9 billion in China and $11.2 billion globally by 2025, indicating a shift from traditional SEO to AI-driven marketing strategies [11][12]. - Companies that own AI models and user behavior data are expected to be the primary beneficiaries of the GEO model, similar to how Google and Baidu benefited during the SEO era [12][13]. Group 3: AI in Healthcare - The AI healthcare sector has shown strong performance, with companies like 泓博医药 and 迪安诊断 seeing over 50% gains year-to-date, driven by increasing market interest [22][24]. - Government policies are increasingly supportive of AI in healthcare, with initiatives aimed at integrating AI into medical services and diagnostics [24][25]. - The article notes that advancements in AI healthcare applications, such as OpenAI's ChatGPT Health, are enhancing market sentiment and could lead to further growth in the sector [26][29]. Group 4: AI in Financial Technology - The financial technology sector has also experienced growth, with a 14% increase in the financial technology ETF as of January 14, 2026 [37]. - AI is expected to enhance the capabilities of both internet finance companies and financial IT firms, improving customer engagement and operational efficiency [38][39]. - However, the article cautions that while AI can improve operational efficiencies, it may not fundamentally change the poor business models prevalent in financial IT companies [40].

Core Viewpoint - The AI healthcare sector is experiencing significant growth and interest in 2026, with the AI healthcare index rising over 11% in just 14 trading days, indicating a clear trend in capital market enthusiasm for this sector [1][2]. Market Performance - As of January 22, 2026, the AI healthcare index increased by over 11%, while the CSI Medical Index and Hang Seng Healthcare Index rose by 7.68% and 10.65%, respectively [1]. - Companies like Di'an Diagnostics and Baolait have seen their stock prices surge over 60%, with others like Weining Health and Chengdu Xian Dao also experiencing gains exceeding 30% [1]. Industry Growth Projections - According to Frost & Sullivan, the AI healthcare market in China is projected to grow from 8.8 billion yuan in 2023 to 315.7 billion yuan by 2033, with a compound annual growth rate (CAGR) of 43.1% [1]. Technological Advancements - Major tech companies are actively entering the AI healthcare space, with OpenAI launching a healthcare version of ChatGPT and other firms like Ant Group, Tencent, JD, and ByteDance developing AI healthcare models and applications [5][6]. - AI drug development is identified as the fastest-growing segment within AI healthcare, with companies like Insilico Medicine and WuXi AppTec significantly reducing drug development timelines [6][7]. Commercialization Challenges - Despite the enthusiasm, the commercialization of AI healthcare products is facing challenges, with many companies reporting losses. For instance, 24 out of 47 biomedicine companies forecasted losses or reduced profits for 2025 [10]. - Companies like KingMed Diagnostics and Anbiping are experiencing significant revenue declines, with Anbiping reporting a 28.29% drop in revenue year-on-year [10][11]. Regulatory Developments - Recent government policies are seen as a positive signal for the AI healthcare sector, with initiatives aimed at promoting and standardizing AI applications in healthcare [15][16]. - The National Healthcare Security Administration has clarified pricing for AI-assisted diagnostic services, which is expected to facilitate the integration of AI into routine clinical practice [15][16]. Future Outlook - Industry experts predict that 2026 will be a pivotal year for AI healthcare, with clearer payment structures and stronger financial backing expected to enhance commercialization prospects [16].

Group 1 - The core viewpoint of the news highlights the strong performance of the pharmaceutical and medical services sectors, with the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index rising by 1.52% as of 11:05 AM on January 23, 2026, driven by significant gains in stocks such as Chengdu Xian Dao (+5.48%) and BGI Genomics (+4.25%) [1] - The Ministry of Commerce and eight other departments have issued opinions to promote high-quality development in the drug retail industry, encouraging retail enterprises to participate in centralized drug procurement and to enhance their bargaining power through joint purchasing [1] - The Chinese pharmaceutical industry is at a pivotal point for global value reassessment, with 2026 being a critical year to validate transformation outcomes, as highlighted by CITIC Securities [1] Group 2 - As of December 31, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index include companies like United Imaging Healthcare and BeiGene, collectively accounting for 48.85% of the index [2] - The CSI Innovation Medicine ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index, providing an easy investment option for those without stock accounts through the linked fund [3]